155 related articles for article (PubMed ID: 19729580)
1. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Menniti FS; Ren J; Coskran TM; Liu J; Morton D; Sietsma DK; Som A; Stephenson DT; Tate BA; Finklestein SP
J Pharmacol Exp Ther; 2009 Dec; 331(3):842-50. PubMed ID: 19729580
[TBL] [Abstract][Full Text] [Related]
2. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Zhang L; Zhang Z; Zhang RL; Cui Y; LaPointe MC; Silver B; Chopp M
Brain Res; 2006 Nov; 1118(1):192-8. PubMed ID: 16959227
[TBL] [Abstract][Full Text] [Related]
3. A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.
Menniti FS; Ren J; Sietsma DK; Som A; Nelson FR; Stephenson DT; Tate BA; Finklestein SP
Restor Neurol Neurosci; 2012; 30(4):283-9. PubMed ID: 22596355
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
Hughes RO; Rogier DJ; Jacobsen EJ; Walker JK; Macinnes A; Bond BR; Zhang LL; Yu Y; Zheng Y; Rumsey JM; Walgren JL; Curtiss SW; Fobian YM; Heasley SE; Cubbage JW; Moon JB; Brown DL; Acker BA; Maddux TM; Tollefson MB; Mischke BV; Owen DR; Freskos JN; Molyneaux JM; Benson AG; Blevis-Bal RM
J Med Chem; 2010 Mar; 53(6):2656-60. PubMed ID: 20196613
[TBL] [Abstract][Full Text] [Related]
5. Effects of the PDE5-inhibitor vardenafil in a mouse stroke model.
Royl G; Balkaya M; Lehmann S; Lehnardt S; Stohlmann K; Lindauer U; Endres M; Dirnagl U; Meisel A
Brain Res; 2009 Apr; 1265():148-57. PubMed ID: 19368809
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
[TBL] [Abstract][Full Text] [Related]
7. Improved sensorimotor function by rolipram following focal cerebral ischemia in rats.
Hätinen S; Sairanen M; Sirviö J; Jolkkonen J
Restor Neurol Neurosci; 2008; 26(6):493-9. PubMed ID: 19096137
[TBL] [Abstract][Full Text] [Related]
8. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging.
Domek-Łopacińska K; Strosznajder JB
Brain Res; 2008 Jun; 1216():68-77. PubMed ID: 18499090
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Kass DA; Champion HC; Beavo JA
Circ Res; 2007 Nov; 101(11):1084-95. PubMed ID: 18040025
[TBL] [Abstract][Full Text] [Related]
10. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
Kang KK; Kim JM; Yu JY; Ahn BO; Yoo M; Kim YC
Int J Urol; 2007 Oct; 14(10):946-51; discussion 951. PubMed ID: 17880297
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
Francis SH; Morris GZ; Corbin JD
Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
[TBL] [Abstract][Full Text] [Related]
12. Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy.
Hirschberg K; Radovits T; Loganathan S; Entz L; Beller CJ; Gross ML; Sandner P; Karck M; Szabó G
J Thorac Cardiovasc Surg; 2009 Jun; 137(6):1508-14. PubMed ID: 19464472
[TBL] [Abstract][Full Text] [Related]
13. The dose-effectiveness of intranasal VEGF in treatment of experimental stroke.
Yang JP; Liu HJ; Wang ZL; Cheng SM; Cheng X; Xu GL; Liu XF
Neurosci Lett; 2009 Sep; 461(3):212-6. PubMed ID: 19559076
[TBL] [Abstract][Full Text] [Related]
14. Magnesium and riboflavin combination therapy following cortical contusion injury in the rat.
Barbre AB; Hoane MR
Brain Res Bull; 2006 May; 69(6):639-46. PubMed ID: 16716831
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia.
Liang S; Pong K; Gonzales C; Chen Y; Ling HP; Mark RJ; Boschelli F; Boschelli DH; Ye F; Barrios Sosa AC; Mansour TS; Frost P; Wood A; Pangalos MN; Zaleska MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):827-35. PubMed ID: 19741150
[TBL] [Abstract][Full Text] [Related]
16. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke.
Hurtado O; Cárdenas A; Pradillo JM; Morales JR; Ortego F; Sobrino T; Castillo J; Moro MA; Lizasoain I
Neurobiol Dis; 2007 Apr; 26(1):105-11. PubMed ID: 17234423
[TBL] [Abstract][Full Text] [Related]
17. Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor.
Liu CQ; Leung FP; Lee VW; Lau CW; Yao X; Lu L; Huang Y
Eur J Pharmacol; 2008 Aug; 590(1-3):250-4. PubMed ID: 18554583
[TBL] [Abstract][Full Text] [Related]
18. Functional recovery after embolic stroke in rodents by activated protein C.
Zlokovic BV; Zhang C; Liu D; Fernandez J; Griffin JH; Chopp M
Ann Neurol; 2005 Sep; 58(3):474-7. PubMed ID: 16130108
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment on: chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
Usta MF
Eur Urol; 2008 Jun; 53(6):1288-9. PubMed ID: 18243512
[No Abstract] [Full Text] [Related]
20. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks.
Silver B; McCarthy S; Lu M; Mitsias P; Russman AN; Katramados A; Morris DC; Lewandowski CA; Chopp M
J Stroke Cerebrovasc Dis; 2009; 18(5):381-3. PubMed ID: 19717023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
